Cite
HARVARD Citation
Edwards, C. et al. (n.d.). THU0416 Disease Activity and Safety During Long-Term (104-Week) Treatment with Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension (Palace 3). Annals of the rheumatic diseases. pp. 348-349. [Online].